Vanadium Complexes with Hydrazone or Thiosemicarbazone Ligands as Potential Anti-Mycobacterium tuberculosis Agents

Autor(es)

de Souza, Paula C. ^[1] ; Maia, Pedro I. S. ^[2] ; de Barros, Heloisa B. ^[1] ; Leite, Clarice Q. F. ^[1] ; Deflon, Victor M. ^[2] ; Pavan, Fernando R. ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ, Sch Pharmaceut Sci, BR-14801902 Araraquara, SP - Brazil

^[2] Univ Sao Paulo, Inst Chem Sao Carlos, BR-13566590 Sao Carlos, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: CURRENT CLINICAL PHARMACOLOGY; v. 10, n. 1, p. 66-72, 2015.
• Citações Web of Science: 1

Resumo

Tuberculosis (TB) is an infectious disease caused mainly by Mycobacterium tuberculosis (MTB) and still an important public health problem worldwide. Some factors like the emergence of multidrug resistant (MDR) and extensively drug-resistant (XDR) strains make urgent the research of new active compounds. Searching for new inorganic compounds against TB, three new dioxovanadium(V) complexes were obtained upon reaction of {[}VO(acac)(2)] with hydrazone and thiosemicarbazone ligands derived from di-2-pyridyl ketone. Spectroscopic studies and X-ray crystallography revealed asymmetrically oxo bridged binuclear complexes of the type {[}[VO(L-1,L-2)](2)(mu-O)(2)], involving the hydrazone ligands, while a mononuclear square pyramidal complex of the type {[}VO2(L-3)] was formed with the thiosemicarbazone ligand. The compounds were tested against M. tuberculosis and three of them, with MICs values between 2.00 and 3.76 mu M were considered promising for TB treatment. Such MIC values are comparable or better than those found for some drugs currently used in TB treatment. (AU)

• Processo FAPESP: 09/54011-8 - EMU: aquisição de difratômetro de raios X de monocristal para análise estrutural de moléculas pequenas e proteínas
• Beneficiário: Victor Marcelo Deflon
• Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários
• Processo FAPESP: 13/14957-5 - Investigação do potencial contra tuberculose de uma nova classe de compostos furoxânicos e compostos nanoestruturados de rutênio(II) e cobre(II)
• Beneficiário: Fernando Rogério Pavan
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 14/11586-9 - Estudos in vitro e in vivo de compostos furoxânicos com potencial aplicação para o tratamento da tuberculose
• Beneficiário: Paula Carolina de Souza
• Modalidade de apoio: Bolsas no Brasil - Doutorado